Table 1.
Demographic and clinical features of 46 patients with Scleroderma-related interstitial lung disease.
Fig 1.
Changes in percentage predicted FVC during mycophenolate mofetil therapy as predicted by mixed model.
FVC indicates forced vital capacity.
Fig 2.
Changes in percentage predicted DLCO During mycophenolate mofetil therapy as predicted by mixed model.
DLCO indicates diffusing capacity of lung for carbon monoxide.
Table 2.
PFT, RVSP, and CALIPER results at baseline and at 6, 12, and 24 months after the start of MMF therapy.
Fig 3.
Changes in RVSP during mycophenolate mofetil therapy as predicted by mixed model.
RVSP indicates right ventricular systolic pressure.
Table 3.
Disease status on computed tomography of the chest at 6, 12, and 24 months after the start of MMF therapy.
Fig 4.
Changes in percentage predicted FVC predicted with mixed model stratified according to the serology of scleroderma.